electroCore announced a leadership transition as CEO Daniel Goldberger plans to retire on April 1, 2026. Joshua Lev, currently CFO, will step in as Interim President, while Michael Fox joins as Chief Operating Officer. This shift comes as the company reports a 27% increase in full-year revenue, reaching $32 million, with significant growth in its Veterans Affairs (VA) channel, driven by products like gammaCore and Quell.
The strong revenue performance highlights electroCore’s successful strategy in expanding its footprint within the VA system, where prescription sales rose to $26 million. The company also noted a promising 31% year-over-year increase in fourth-quarter revenue, alongside an improved gross margin of 87%. However, the net loss widened to $14 million, emphasizing the need for continued operational efficiency amid rising SG&A expenses.
Investors should monitor the upcoming launch of the Quell OTC product and the strategic partnership with Kaiser, as these developments could further enhance revenue streams and market penetration. The leadership transition, while significant, is positioned to maintain operational continuity and drive growth in 2026 and beyond.
Source: fool.com